Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Oncogene

• Publication date

  2014-01-30

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/onc.2012.625PMID 23334330
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Functional viability profiles of breast cancer.

  2011cited by this paper
• Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

  2011cited by this paper
• Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.

  2011cited by this paper
• Cyclin e amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

  2011cited by this paper
• Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

  2011cited by this paper
• Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

  2011cited by this paper
• Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib

  2010cited by this paper
• Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.

  2010cited by this paper
• Genome profiling of ERBB2-amplified breast cancers

  2010cited by this paper
• High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer

  2010cited by this paper
• A census of amplified and overexpressed human cancer genes

  2010cited by this paper
• Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines

  2010cited by this paper
• DNA amplifications in breast cancer: genotypic-phenotypic correlations.

  2010cited by this paper
• ROCK: a breast cancer functional genomics resource

  2010cited by this paper
• Identification of primary gene targets of TFAP2C in hormone responsive breast carcinoma cells

  2010cited by this paper
• An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers

  2010cited by this paper
• A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines

  2009cited by this paper
• AP‐2γ promotes proliferation in breast tumour cells by direct repression of the CDKN1A gene

  2009cited by this paper
• Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis

  2009cited by this paper
• Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti‐hormone therapy and reduced patient survival

  2009cited by this paper
• Identification of target genes of transcription factor activator protein 2 gamma in breast cancer cells

  2009cited by this paper
• Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

  2009cited by this paper
• Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers

  2009cited by this paper
• The genomic profile of HER2‐amplified breast cancers: the influence of ER status

  2008cited by this paper
• Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines

  2008cited by this paper
• EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer

  2008cited by this paper
• Screening for copy‐number alterations and loss of heterozygosity in chronic lymphocytic leukemia—A comparative study of four differently designed, high resolution microarray platforms

  2008cited by this paper
• A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.

  2008cited by this paper
• Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

  2008cited by this paper
• Comparative Genomic Hybridisation Arrays: High-Throughput Tools to Determine Targeted Therapy in Breast Cancer

  2008cited by this paper
• Wwox and Ap2γ Expression Levels Predict Tamoxifen Response

  2007cited by this paper
• Wwox and Ap2gamma expression levels predict tamoxifen response.

  2007cited by this paper
• Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer

  2007cited by this paper
• Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers

  2007cited by this paper
• 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

  2007cited by this paper
• Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

  2007cited by this paper
• Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas

  2007cited by this paper
• Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.

  2006cited by this paper
• Analysis of cell-based RNAi screens

  2006cited by this paper
• The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis

  2006cited by this paper
• Novel patterns of genome rearrangement and their association with survival in breast cancer.

  2006cited by this paper
• Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization

  2006cited by this paper
• RNA interference‐based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes

  2006cited by this paper
• Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

  2006cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• Distal ERBB2 Promoter Fragment Displays Specific Transcriptional and Nuclear Binding Activities inERBB2 Overexpressing Breast Cancer Cells

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis

  2003cited by this paper
• Addiction to Oncogenes--the Achilles Heal of Cancer

  2002cited by this paper
• First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report.

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report.

  2001cited by this paper
• A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

  1999cited by this paper
• Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways.

  1998cited by this paper
• The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma.

  1995cited by this paper
• A Preliminary Report

  1953cited by this paper
• Edinburgh Research Explorer Identification of HTF (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression

  year unknowncited by this paper

• Letter re: Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2

  2025cites this paper
• HER2 mRNA Levels, Estrogen Receptor Activity and Susceptibility to Trastuzumab in Primary Breast Cancer

  2022cites this paper
• Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs

  2022cites this paper
• Duocarmycin-based antibody-drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: pharmaceutical strategy and clinical progress.

  2021cites this paper
• Co-expression of transcription factor AP-2beta (TFAP2B) and GATA3 in human mammary epithelial cells with intense, apicobasal immunoreactivity for CK8/18

  2021cites this paper
• SynLeGG: analysis and visualization of multiomics data for discovery of cancer ‘Achilles Heels’ and gene function relationships

  2021cites this paper
• Concordance of Genomic Alterations between Circulating Tumor DNA and Matched Tumor Tissue in Chinese Patients with Breast Cancer

  2020cites this paper
• A TFAP2C Gene Signature Is Predictive of Outcome in HER2-Positive Breast Cancer

  2019cites this paper
• Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate

  2019cites this paper
• PATRI, a Genomics Data Integration Tool for Biomarker Discovery

  2018cites this paper
• Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2β

  2018cites this paper
• Intratumor lactate levels reflect HER2 addiction status in HER2‐positive breast cancer

  2018cites this paper
• Bioinformatic identification of disease driver networks using functional profiling data

  2018cites this paper
• Role Of d16HER2 Splice Variant In Breast Cancer Stem Cells

  2018cites this paper
• Gene expression profiling of breast tumours from New Zealand patients.

  2017cites this paper
• MiR-214 protects MC3T3-E1 osteoblasts against H2O2-induced apoptosis by suppressing oxidative stress and targeting ATF4.

  2017cites this paper
• Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host

  2017cites this paper
• Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer

  2016cites this paper
• Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer

  2016cites this paper
• miR-214 as a key hub that controls cancer networks: small player, multiple functions.

  2015cites this paper
• The role of Tcfap2c in tumorigenesis and cancer growth in an activated Neu model of mammary carcinogenesis

  2015cites this paper
• A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis

  2015cites this paper
• Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.

  2014cites this paper
• Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast

  2014cites this paper
• Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers

  2014cites this paper
• BIM, PUMA, and the Achilles’ Heel of Oncogene Addiction

  2013cites this paper
• ROCK: a resource for integrative breast cancer data analysis

  2013cites this paper
• From integrative genomics to therapeutic targets.

  2013influential citation